BC Week In Review | Sep 22, 2014
Clinical News

CTP-730: Phase I started

Concert began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single doses of 5, 10, 20, 30 and 40 mg oral CTP-730 in up to 40 healthy volunteers. Concert and Celgene are partnered to...
Items per page:
1 - 1 of 1